Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women

BACKGROUND: The integrase inhibitor regimen [elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (TDF)] demonstrated superior efficacy when compared with a protease inhibitor regimen [ritonavir-boosted atazanavir (ATV + RTV) and FTC/TDF] in 575 treatment-naive women at week 48. We in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Acquir Immune Defic Syndr
Hauptverfasser: Hodder, Sally, Squires, Kathleen, Kityo, Cissy, Hagins, Debbie, Avihingsanon, Anchalee, Kido, Anna, Jiang, Shuping, Kulkarni, Rima, Cheng, Andrew, Cao, Huyen
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6425939/
https://ncbi.nlm.nih.gov/pubmed/29481486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000001663
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge